Table 1.
Characteristics of 137 patients treated with sunitinib due to advanced GIST
| Clinicopathological features | No of patients (%) | |
|---|---|---|
| Total number of patients | 137 (100) | |
| Age [years] at the start of therapy with sunitinib | Median (range) | 55 (15-82) |
| ≤45 | 14 (10) | |
| > 45 | 123 (88) | |
| Gender | Female | 63 (46) |
| Male | 74 (54) | |
| Primary tumor site | Stomach | 46 (33.5) |
| small bowel | 79 (57.6) | |
| large bowel/rectum | 4 (2.9) | |
| other or intraperitoneally with unknown primary origin | 8 (5.8) | |
| Time on imatinib therapy | ≤ 6 months (early resistance) | 25 (18.2) |
| 6-12 months | 16 (11.7) | |
| > 12 months | 96 (70.1) | |
| Primary reason for stop of imatinib therapy | Disease progression | 135 (98.5) |
| Imatinib intolerance | 2 (1.5) | |
| ECOG Performance Status | 0 | 48 (35) |
| 1 | 72 (52.6) | |
| ≥2 | 17 (12.4) | |
| Tumor genotype* | Exon 11 KIT mutation | 52 (58.4) |
| Exon 9 KIT mutation | 15 (16.9) | |
| PDGFRA mutation | 12 (13.5) | |
| Wild-type | 10 (11.2) | |
| Data not available | 48 | |
* mutational status was evaluated in 89 cases (65%)